Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
  Author: Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, ...

Read More >>
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
  Author: Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeu...

Read More >>
Kazia to team up with U.S. oncology group for brain cancer drug trial
  Author: Mateen Dalal

A multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate Kazia Therapeutics Ltd, an Australian onco...

Read More >>
GSK, Zymeworks expand partnership for bispecific antibody development
  Author: Nikita Chaurasia

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopha...

Read More >>
Vertex, Kymera join forces for developing protein degradation drugs
  Author: Nikita Chaurasia

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incor...

Read More >>
Roche delays acquiring Spark as regulatory review process continues
  Author: Mateen Dalal

Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of...

Read More >>
Veeba Foods ventures into child nutrition segment with V-Nourish
  Author: Mateen Dalal

Condiments and sauce manufacturer Veeba Foods reportedly ventured into child nutrition segment with a new health beverage, V-Nourish. According to sources close to the matter, V-Nou...

Read More >>
Pfizer obtains FDA approval for oral heart drug costing $225K a year
  Author: Nikita Chaurasia

In May the drug received FDA breakthrough status and had lowered the risk of death for patients by 30% as compared to placebo The U.S. Food and Drug Administration ...

Read More >>
Cytokinetics declares FORTITUDE-ALS results from reldesemtiv study
  Author: Nikita Chaurasia

FORTITUDE-ALS did not attain statistical importance in its primary endpoint of change from baseline in SVC Patients who received reldesemtiv in FORTITUDE-AL...

Read More >>
Context Therapeutics begins Phase 2 Apristor trial for cancer patients
  Author: Mateen Dalal

The latest study will assess Apristor’s safety plus pharmacological profile in patients, besides the biomarker analyses, for exploring the drug’s predictive response factors. ...

Read More >>
Audentes exhibits new positive data from the ASPIRO clinical trial
  Author: Mateen Dalal

The leading American AAV-based genetic medicines company, Audentes Therapeutics Inc., has reportedly presented new positive data from ASPIRO, the AT132 Phase 1/2 clinical trial for the treatment of XLMTM (X-linked Myot...

Read More >>
Norton Healthcare & Select Medical tie up on outpatient rehabilitation
  Author: Nikita Chaurasia

In a recent turn of events, Norton Healthcare and Select Medical have reportedly declared signing a joint venture agreement intended to assimilate outpatient rehabilitation solutions in the Southern Indiana and Louisville metro provinces. ...

Read More >>
Oxurion & Bicycle Therapeutics declare full enrollment for DME study
  Author: Nikita Chaurasia

Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase...

Read More >>
Precision BioSciences doses first patient in CAR T cell therapy trial
  Author: Nikita Chaurasia

Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm   The company believes that the patien...

Read More >>
BioTime to present OpRegen® Phase I/IIa study outcomes at ARVO 2019
  Author: Nikita Chaurasia

BioTime Incorporation, a clinical stage biotechnology firm developing newfangled cellular treatments, has recently declared that updated outcomes from a Phase I/IIa clinical study of OpRegen®, its chief product can...

Read More >>
FDA approves Gelesis prescription weight-loss drug Plenity for adults
  Author: Mateen Dalal

Plenity is has been cleared for obese or overweight adults having a body mass index of at least 25 Reports confirm that the U.S. Food and Drug Administration (FDA) ...

Read More >>
Assembly Biosciences reveals data from Phase 2a studies of ABI-H0731
  Author: Mateen Dalal

The data received to date is directionally correct and reduction in HBeAg and HBsAg have been observed in some individuals in both studies. U.S. based clinical-stag...

Read More >>
Inscripta raises additional $20 million in Series C financing round
  Author: Nikita Chaurasia

Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing ...

Read More >>
Cyclacel unveils Phase 1 clinical data for its breast cancer treatment
  Author: Mateen Dalal

·         The data was presented at the American Association for Cancer Research Annual Meeting 2019 ·  ...

Read More >>
Imvax unveils positive results from clinical trial of IGV-001 vaccine
  Author: Nikita Chaurasia

Clinical-stage biotechnology company Imvax, Inc., committed to creating novel patient-specific vaccines and immunotherapy strategies, has reportedly attained positive results from an ongoing Phase 1b clinical trial tha...

Read More >>
Partners HealthCare to fully integrate its EHR system with MassPAT
  Author: Mateen Dalal

Partners Healthcare has now become the first healthcare network to have the tool immediately available to doctors at the point-of-care in Massachusetts. Partners He...

Read More >>
Biogen to wholly acquire gene therapy firm Nightstar Therapeutics
  Author: Mateen Dalal

Nightstar’s agreement with Biogen will give the company the platform and resources it needs to expand its mission to restore sight in patients with inherited retinal diseases. ...

Read More >>
Merck offers $5-9B for Versum Materials to challenge bid from Entegris
  Author: Mateen Dalal

The company is apparently looking to buy the electronic materials maker for bolstering its Performance Materials division Merck KGaA, the laboratory supplies provid...

Read More >>
MPM Capital secures $400M to finance innovative biotech startups
  Author: Mateen Dalal

The fund would reportedly contribute toward disruptive scientific developments across a spate of therapeutic areas such as immunology, oncology, and neurosciences. ...

Read More >>
AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
  Author: Nikita Chaurasia

The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial Anti-Tau monoclonal antibody was det...

Read More >>
U.S. FDA to clampdown potentially perilous dietary supplements
  Author: Mateen Dalal

Council for Responsible Nutrition welcomed the action against companies that have tarnished consumer confidence for all legitimate products. The U.S. Food and Drug ...

Read More >>
Merck to invest $70m for R&D facility expansion in Massachusetts
  Author: Mateen Dalal

The building construction is scheduled to be completed in 2021 and is designed to offer office space, wet labs and a cafeteria. Merck, one of the leaders in the pha...

Read More >>
Thermo Fisher to collaborate with Torque to develop Slipstream™
  Author: Mateen Dalal

The Torque-Thermo Fisher manufacturing facility is expected to come online by the end of 2019. Thermo Fisher Scientific Inc., the biotechnology products development...

Read More >>
UK university uses graphene to develop lung cancer detection device
  Author: Mateen Dalal

The new device possesses the potential to detect specific lung cancer markers at the earliest stage possible. In what may seem to a pathbreaking revolutionary finding i...

Read More >>
U.S. FDA approves first generic drug for asthma and COPD treatment
  Author: Mateen Dalal

The generic drug will mean low cost but high-quality drug access to people suffering from chronic respiratory and lung diseases. The U.S. Food and Drug Administrati...

Read More >>
Roche to abandon Alzheimer’s drug crenezumab following failed trials
  Author: Nikita Chaurasia

The news from Roche marks another failure in developing drugs for Alzheimer’s after many other drugmakers have stopped trials of prospective treatments. Roche...

Read More >>
AstraZeneca inks a value-based agreement with UPMC Health Plan
  Author: Mateen Dalal

The deal links reimbursement for the blood thinner to the cardiovascular outcomes of patients.   Sources familiar with the development ...

Read More >>
Purdue Pharma teams up with Alivio Therapeutics to advance ALV-107
  Author: Mateen Dalal

Purdue Pharma L.P., the Connecticut-based pharmaceutical company, has reportedly announced that it has signed a partnership agreement with Alivio Therapeutics to advance one of its product candidates via clinical devel...

Read More >>
Abcam acquires California-based antibodies developer Calico Biolabs
  Author: Nikita Chaurasia

U.K. biotech firm Abcam has recently confirmed the acquisition of Calico Biolabs, a specialist in rabbit monoclonal antibodies based out of California. Calico is known to provide custom, high-quality recombinant rabbit...

Read More >>
Basilea & Roche to jointly study novel treatment for urothelial cancer
  Author: Nikita Chaurasia

The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. ...

Read More >>